Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Services
    Clinical Research ServicesCommercial PositioningConsultingEarly ClinicalStrategic SolutionsLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read more
    Innovation
    FIRECRESTICON Digital PlatformSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGEMedical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMSICOMaster for eTMFControl TowerPrism eClinical Solution
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Harmonising data and services for more integrated decentralised clinical trials.
    ICON Digital Platform

    Harmonising data and services for more integrated decentralised clinical trials.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    Register today
    Webinar: Medicare Part D - Price negotiation panel discussion

    Register today

    Register today
    Webinar: Rare disease week 2023 - Exploring accessibility in rare disease clinical research

    Register today

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON CARES is our commitment to making a positive impact on our people, environment and our community.
    Environmental, Social and Governance

    ICON CARES is our commitment to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 27 November 2019

    ICON plc to Present at Evercore ISI 2nd Annual HealthCONx Conference

    Wednesday, November 27, 2019.

  • 14 November 2019

    ICON plc to Present at Jefferies 2019 London Healthcare Conference

    Thursday, November 21, 2019.

  • 23 October 2019

    ICON’s Acquisition of Symphony Clinical Research

    The acquisition further enhances ICON’s patient, site and data strategy and complements ICON’s existing PMG Research and MeDiNova Research site networks in the US and EMEA.

  • 23 October 2019

    ICON Reports Third Quarter 2019 Results

    Quarter 3 reported revenue of $710.4 million. This represents strong year on year growth of 8.5% or 9.5% on a constant currency basis.

  • 3 September 2019

    ICON plc to Present at Baird’s 2019 Global Healthcare Conference

    Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will present

  • 24 July 2019

    ICON Reports Second Quarter 2019 Results

    Net business wins (including pass-through) in the quarter of $901 million; a book to bill of 1.30.

  • 24 July 2019

    ICON announces the appointment of Ms. Julie O’Neill to Board of Directors

    And confirms the retirement of Professor Dermot Kelleher and Mr. Declan McKeon

  • 2 July 2019

    Forbes names ICON in list of Best Employers in America for Women

    ICON recognised as top employer for women in anonymous survey of 60,000 employees.

  • 24 June 2019

    ICON and DIA driving Insights to Action with DIA Live 2019

    DIA Live combines powerful AI analysis and data visualisation features of news and social media conversations at DIA Global Annual Meeting.

  • 23 May 2019

    ICON’s Acquisition of MeDiNova Research

    The acquisition further enhances ICON’s patient recruitment capabilities in EMEA and complements ICON’s existing site network in the US, PMG Research.

  • 1
  • ...
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 15
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON Spokespeople
  • Awards
  • Events
    • Industry events
      • SCOPE 2023
      • ASCO 2023
    • Webinars
    • Workshops
    • Financial Times Global Pharmaceutical and Biotechnology Conference
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2023 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies
  • International Transfers

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media